Review

vegf a (Miltenyi Biotec)

Miltenyi Biotec is a verified supplier

Miltenyi Biotec manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Miltenyi Biotec vegf a
Vegf A, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/premium+grade/Human+VEGF+(165)+IS%2C+premium+grade/pmc13380759-111-13-17
Average 94 stars, based on 26 article reviews

vegf a - by Bioz Stars, 2026-09

94/100 stars

Images

Recombinant:

Article Title: Generation of Intestinal and Colonic Organoids Derived From Human Pluripotent Stem Cells
Article Snippet: Reagents mTeSR1 (mTeSR 1, Stem Cell Technologies, cat. no. 85850) CS10 (CryoStor CS10, Stem Cell Technologies, cat. no. 100‐1061) XF solution (StemMACS Passaging Solution XF, Miltenyi Biotec, cat. no. 130‐104‐688) Dispase (5 U/mL dispase in Hanks' Balanced Salt Solution, Stem Cell Technologies, cat. no.07913) DPBS ‐/‐ 1X (Dulbecco's Phosphate Buffered Saline without Calcium and Magnesium, Eurobio, cat. no. CS1PBS0101) ROCKi (ROCK specific inhibitor, Y27632, StemCell Technologies, cat. no. 72304) DMEM/F12 (Gibco Dulbecco's Modified Eagle Medium, F12 nutrients, HEPES, Life Technologies, cat. no. 31330038) RPMI Gibco (Roswell Park Memorial Institute Medium 1640, Glutamine, Life Technologies, cat. no. 21875034) Accutase (ACCUTASE, StemCell Technologies, cat. no. 07920) Act. .. A (Human recombinant Activin A premium grade, Miltenyi Biotec, cat. no. 130‐115‐011). ..

Article Title: Dynamic estimation of metabolic state during CAR T cell production
Article Snippet: .. Recombinant Human IL-2 IS, premium grade , Miltenyi Biotec , Cat# 130-097-748. .. CryoStor CS10 , STEMCELL Technologies , # 07930.

Isolation:

Article Title: Cellular Immunological Memory T Cells and IL15RA Gene Polymorphism in COVID-19 Vaccinated Individuals from Southern Brazil
Article Snippet: .. Isolated PBMCs were distributed into three microtubes containing specific reagents: (1) Stimulated Culture: 1 μg/mL of PepTivator SARS-CoV-2 Select premium grade (Milteny Biotec, Bergish Gladbach, Germany, #cat 130-127-309) [ ], 1% Penicillin-Streptomycin (Gibco, Thermo Fisher Scientific, Waltham, MA, US, $cat), 20% autologous serum, 1 × 10 6 isolated PBMCs, and RPMI-1640 medium to a final volume of 200 μL. (2) Unstimulated Culture: 1% Penicillin-Streptomycin, 20% autologous serum, 1 × 10 6 isolated PBMCs, and RPMI-1640 medium to a final volume of 200 μL. (3) Control Culture: 5 μg/mL of Phytohemagglutinin, M form (PHA-M, Gibco, Thermo Fisher Scientific, Waltham, MA, US, #cat: 10576015), 1% Penicillin-Streptomycin, 20% autologous serum, 1 × 10 6 isolated PBMCs, and RPMI-1640 medium to a final volume of 200 μL. ..

Article Title: Longitudinal Evaluation of Humoral and Cellular Immunity After BNT162b2 COVID-19 Vaccination: Influence of Booster Type, Infection and Chronic Health Conditions.
Article Snippet: The SARS-CoV-2 Prot_S T Cell Analysis Kit (Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach; Germany) was used to evaluate SARS-CoV-2-specific T-cell responses. .. Isolated PBMCs (1 × 106), thawed or fresh, were rested at 37 ◦C overnight and then cultured in 96-well plates with a pool of 15-mer peptides overlapping by 11 amino acids covering the complete coding sequence (amino acids 5–1273) of the SARS-CoV-2 spike (S) glycoprotein (GenBank MN908947.3, protein QHD43416.1), supplied as PepTivator® SARS-CoV-2 Prot_S Complete, premium grade (Miltenyi Biotech). ..

Control:

Cell Culture:

Sequencing:

other:

Article Title: Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression
Article Snippet: Human TNF-α, premium grade , Miltenyi Biotec , Cat# 130-094-014.

Image Search Results

Activation-induced marker assays are inherently variable and detect heterogeneous subsets of activated CD4 + T cells (A–D) Representative flow cytometry data and quantification of paired raw unstimulated and pp65-stimulated AIM + frequencies among CD4 + T cells (A and B) and CD8 + T cells (C and D). CV (%) is displayed above the responses for each donor. (E and F) Source(s) of variance in CD4 + (E) and CD8 + (F) AIM + cell frequencies calculated after subtracting the corresponding unstimulated AIM + frequencies, using mixed effects analysis, with donor and experiment (technical replicate) as random effects. Graphs show variance components as the percentages of total variance. (G and H) Uniform manifold approximation and projection (UMAP) analysis was performed on CD4 + (G) and CD8 + (H) total AIM + T cells, defined by co-expression of at least one AIM pair. (I and J) FlowSOM clustering of total AIM + CD4 + T cells. (I) Each circle represents one cluster and its relative marker expression; similar clusters are grouped into 8 metaclusters (colored rings); cluster/metacluster spatial proximity indicates similarity. (J) Heatmap showing relative marker expression in the 8 FlowSOM metaclusters. (K) AIM + CD4 + T cell percentages within each FlowSOM metacluster across individual donors. Replicate AIM assays were performed on cryopreserved PBMCs from 5 donors, with 4–8 technical replicates per donor across 2–4 independent experiments; PBMCs were stimulated for 20 h with CMV pp65 peptides. Total AIM + populations from pp65-stimulated samples were pooled from all donors and technical replicates (G–J) or all technical replicates within each donor (K) prior to analysis.

Journal: Cell Reports Methods

Article Title: Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows

doi: 10.1016/j.crmeth.2026.101458

Figure Lengend Snippet: Activation-induced marker assays are inherently variable and detect heterogeneous subsets of activated CD4 + T cells (A–D) Representative flow cytometry data and quantification of paired raw unstimulated and pp65-stimulated AIM + frequencies among CD4 + T cells (A and B) and CD8 + T cells (C and D). CV (%) is displayed above the responses for each donor. (E and F) Source(s) of variance in CD4 + (E) and CD8 + (F) AIM + cell frequencies calculated after subtracting the corresponding unstimulated AIM + frequencies, using mixed effects analysis, with donor and experiment (technical replicate) as random effects. Graphs show variance components as the percentages of total variance. (G and H) Uniform manifold approximation and projection (UMAP) analysis was performed on CD4 + (G) and CD8 + (H) total AIM + T cells, defined by co-expression of at least one AIM pair. (I and J) FlowSOM clustering of total AIM + CD4 + T cells. (I) Each circle represents one cluster and its relative marker expression; similar clusters are grouped into 8 metaclusters (colored rings); cluster/metacluster spatial proximity indicates similarity. (J) Heatmap showing relative marker expression in the 8 FlowSOM metaclusters. (K) AIM + CD4 + T cell percentages within each FlowSOM metacluster across individual donors. Replicate AIM assays were performed on cryopreserved PBMCs from 5 donors, with 4–8 technical replicates per donor across 2–4 independent experiments; PBMCs were stimulated for 20 h with CMV pp65 peptides. Total AIM + populations from pp65-stimulated samples were pooled from all donors and technical replicates (G–J) or all technical replicates within each donor (K) prior to analysis.

Article Snippet: Cells were incubated for 6, 20 or 44 h with media, 1.5 μg/mL PepTivator CMV pp65 (Miltenyi), 3.3 μg/mL CMV pp65 recombinant protein (Miltenyi), 1 μg/mL PepTivator SARS-CoV-2 Prot_S (Miltenyi), or 1/100 Infanrix hexa (GSK) or 1/400 CytoStim (Miltenyi).

Techniques: Activation Assay, Marker, Flow Cytometry, Expressing

Journal: Cell Reports Methods

Article Title: Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows

doi: 10.1016/j.crmeth.2026.101458

Figure Lengend Snippet: Box-Cox transformation-based correction for background enhances signal detection and reduces variability (A) Re-analysis of AIM assay data from SARS-CoV-2 spike peptide-stimulated PBMCs from solid organ transplant recipients ( n = 33) vaccinated with three doses of a COVID-19 mRNA vaccine (PREVENT cohort), or (B) new analysis of CMV pp65-stimulated PBMCs from 6 healthy donors across 3 independent experiments at each of 4 research centers in the CAN-ASC cohort ( n = 52 total). Shown are correlation and linear regression analyses of unstimulated AIM + frequencies with raw antigen-stimulated AIM + frequencies, net responses after subtracting or dividing by the unstimulated condition. CD134 + CD25 + of CD4 + T cells and CD137 + CD69 + of CD8 + T cells are presented. p values are from Spearman’s correlation tests. Solid lines represent linear regression with error bars indicating 95% confidence intervals (CIs). For the CAN-ASC cohort, regression and correlation analyses were performed after correcting for between-donor variations. (C) Box-Cox transformation workflow to correct for AIM + cells in unstimulated controls, using a user-defined parameter λ ϵ[0,1], yielding a stimulation index (SI). (D and E) Three statistical methods to estimate optimal λ values by minimizing correlation between the unstimulated and net stimulated AIM values. Left: linear regression to identify λ giving the highest probability of zero slope ( β ˆ = 0 ), expressed as a posterior probability distribution for λ. Center: Spearman’s correlation to identify the value of λ producing an estimated zero correlation. Right: likelihood profile for λ based on linear regression to estimate the probable optimal value of λ. Values were estimated for (D) PREVENT or (E) CAN-ASC cohorts. (F) ICC values as a function of λ in the CAN-ASC cohort, using the SI for CD4 + and CD8 + AIM responses to CMV pp65. Gray dotted lines show ICC values for raw (untransformed) AIM + frequencies. (G) Comparison of bootstrap-adjusted CVs calculated between technical replicates within donors for raw AIM + frequencies, net subtraction-/division-corrected AIM + frequencies/ratios, or Box-Cox-corrected SIs. Each point is the bootstrap-adjusted CV of technical replicates from one donor. p values represent Dunnett’s multiple comparisons test following one-way repeated-measures ANOVA. (H and I) Re-analysis of AIM responses for the PREVENT cohort throughout a three-dose COVID-19 mRNA vaccination schedule calculated by subtracting or dividing by unstimulated AIM + frequencies, or Box-Cox-corrected SI values. p values represent Dunnett’s multiple comparisons test following mixed-effects analysis of log 2 -transformed data. Bold p values denote significant differences between time points detected only with Box-Cox-corrected SI values.

Techniques: Transformation Assay, Comparison

AIM responses are reliably detectable across various cell sources (A) Percentage viable of total CD3 + T cells in AIM assays. Error bars represent SD. p values represent comparisons using Dunn’s multiple comparisons test following Friedman test. (B–E) Representative flow cytometry (B and C) and SI quantification (D and E) for each AIM relative to the unstimulated control among CD4 + (B and D) and CD8 + (C and E) T cells from each cell source. (F) Ratio of AIM SIs between CMV pp65 protein- and peptide-stimulated CD4 + T cells in relation to cell source. Positive or negative ratios indicate greater detection of AIM responses with whole protein or peptide stimulation, respectively, while 95% CIs overlapping zero indicate no significant difference between protein and peptide stimulation. AIM responses using fresh whole blood, fresh PBMCs, or cryopreserved PBMCs (PBMC-C), with or without a 24-h delay in processing (−24 h) are compared. Cells were rested overnight and stimulated for 20 h with CMV pp65 peptides, CMV pp65 whole protein, or Infanrix vaccine. Error bars are 95% CIs calculated on a log 2 scale (D, E and F), and data are from n = 6 healthy donors (A–F).

Journal: Cell Reports Methods

Article Title: Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows

doi: 10.1016/j.crmeth.2026.101458

Figure Lengend Snippet: AIM responses are reliably detectable across various cell sources (A) Percentage viable of total CD3 + T cells in AIM assays. Error bars represent SD. p values represent comparisons using Dunn’s multiple comparisons test following Friedman test. (B–E) Representative flow cytometry (B and C) and SI quantification (D and E) for each AIM relative to the unstimulated control among CD4 + (B and D) and CD8 + (C and E) T cells from each cell source. (F) Ratio of AIM SIs between CMV pp65 protein- and peptide-stimulated CD4 + T cells in relation to cell source. Positive or negative ratios indicate greater detection of AIM responses with whole protein or peptide stimulation, respectively, while 95% CIs overlapping zero indicate no significant difference between protein and peptide stimulation. AIM responses using fresh whole blood, fresh PBMCs, or cryopreserved PBMCs (PBMC-C), with or without a 24-h delay in processing (−24 h) are compared. Cells were rested overnight and stimulated for 20 h with CMV pp65 peptides, CMV pp65 whole protein, or Infanrix vaccine. Error bars are 95% CIs calculated on a log 2 scale (D, E and F), and data are from n = 6 healthy donors (A–F).

Techniques: Flow Cytometry, Control

A 20-h stimulation period reliably detects most CD4 + and CD8 + T cell AIMs Fresh whole blood or cryopreserved PBMCs (PBMC-C) were stimulated with CMV pp65 peptides for 6, 20, or 44 h. (A) Representative CD134 + CD25 + frequencies of CD4 + T cells. (B) SI quantification of AIM + CD4 + T cells. (C) Representative CD137 + CD69 + frequencies of CD8 + T cells. (D) SI quantification of AIM + CD8 + T cells. p values represent one-sample t tests (B and D), with AIM signals considered present when the mean log 2 -transformed SI significantly differed from zero. Paired samples are from n = 4 healthy donors (A–D).

Journal: Cell Reports Methods

Article Title: Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows

doi: 10.1016/j.crmeth.2026.101458

Figure Lengend Snippet: A 20-h stimulation period reliably detects most CD4 + and CD8 + T cell AIMs Fresh whole blood or cryopreserved PBMCs (PBMC-C) were stimulated with CMV pp65 peptides for 6, 20, or 44 h. (A) Representative CD134 + CD25 + frequencies of CD4 + T cells. (B) SI quantification of AIM + CD4 + T cells. (C) Representative CD137 + CD69 + frequencies of CD8 + T cells. (D) SI quantification of AIM + CD8 + T cells. p values represent one-sample t tests (B and D), with AIM signals considered present when the mean log 2 -transformed SI significantly differed from zero. Paired samples are from n = 4 healthy donors (A–D).

Techniques: Transformation Assay

CD134 and CD137 optimally detect antigen-specific Tregs (A) Representative flow cytometric gating strategy for FOXP3 + HELIOS + Tregs. (B) Effect of stimulation with CMV pp65 peptides on FOXP3 + and FOXP3 + HELIOS + frequencies in CD4 + T cells. p values represent Tukey’s multiple comparisons test following two-way ANOVA. (C–E) SI and representative flow cytometry for AIM pairs and Boolean combinations in FOXP3 + HELIOS + Tregs following stimulation of cryopreserved PBMCs with pp65 peptides or whole protein, SARS-CoV-2 spike peptides, or Infanrix combination vaccine for 20 h. Boolean AND/OR gating combinations comprise CD134/CD69, CD134/CD137, and CD137/CD69 (3xAIM); or 3xAIM plus CD154/CD69, CD134/CD154, and CD137/CD154 (6xAIM). Mean log 2 -transformed Box-Cox-corrected SIs are shown. (F) Gating strategy to evaluate CD39 + frequencies among CD134 + CD137 + and non-CD134 + CD137 + FOXP3 + HELIOS + Tregs and FOXP3/HELIOS − Tconvs. (G) Median percentages of CD39 + among CD134 + CD137 + or non-CD134 + CD137 + CD4 + FOXP3 + HELIOS + Tregs or conventional FOXP3/HELIOS − T cells. p values represent Dunnett's multiple comparisons test following repeated measures one-way ANOVA on log2-transformed data. (H) Positive predictive value (PPV) of CD39 or CD39, CD134, and CD137 as markers for antigen-specific Tregs (CD134 + CD137 + FOXP3 + HELIOS + ). Error bars represent 95% confidence intervals of the mean (C, E, and H) or interquartile ranges (G). Healthy donors: n = 9 (pp65 and Infanrix 20-h stimulations) and n = 4 (all others).

Journal: Cell Reports Methods

Article Title: Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows

doi: 10.1016/j.crmeth.2026.101458

Figure Lengend Snippet: CD134 and CD137 optimally detect antigen-specific Tregs (A) Representative flow cytometric gating strategy for FOXP3 + HELIOS + Tregs. (B) Effect of stimulation with CMV pp65 peptides on FOXP3 + and FOXP3 + HELIOS + frequencies in CD4 + T cells. p values represent Tukey’s multiple comparisons test following two-way ANOVA. (C–E) SI and representative flow cytometry for AIM pairs and Boolean combinations in FOXP3 + HELIOS + Tregs following stimulation of cryopreserved PBMCs with pp65 peptides or whole protein, SARS-CoV-2 spike peptides, or Infanrix combination vaccine for 20 h. Boolean AND/OR gating combinations comprise CD134/CD69, CD134/CD137, and CD137/CD69 (3xAIM); or 3xAIM plus CD154/CD69, CD134/CD154, and CD137/CD154 (6xAIM). Mean log 2 -transformed Box-Cox-corrected SIs are shown. (F) Gating strategy to evaluate CD39 + frequencies among CD134 + CD137 + and non-CD134 + CD137 + FOXP3 + HELIOS + Tregs and FOXP3/HELIOS − Tconvs. (G) Median percentages of CD39 + among CD134 + CD137 + or non-CD134 + CD137 + CD4 + FOXP3 + HELIOS + Tregs or conventional FOXP3/HELIOS − T cells. p values represent Dunnett's multiple comparisons test following repeated measures one-way ANOVA on log2-transformed data. (H) Positive predictive value (PPV) of CD39 or CD39, CD134, and CD137 as markers for antigen-specific Tregs (CD134 + CD137 + FOXP3 + HELIOS + ). Error bars represent 95% confidence intervals of the mean (C, E, and H) or interquartile ranges (G). Healthy donors: n = 9 (pp65 and Infanrix 20-h stimulations) and n = 4 (all others).

Techniques: Flow Cytometry, Transformation Assay

CMV- and SARS-CoV-2-specific AIM assays are reproducible within and between research centers (A) Experimental design for AIM assay inter-site testing. Replicate aliquots of PBMCs from n = 6 healthy donors assayed in three independent experiments (individual points) by four research groups (coded A–D). Replicate AIM assay experiments ( n = 3 per donor, per site) were performed by stimulating PBMCs for 20 h with CMV pp65 or SARS-CoV-2 spike peptides. (B and C) Box-Cox-corrected SIs of CD134 + CD25 + frequencies among CD4 + T cells and CD137 + CD69 + among CD8 + T cells. Means and SD of log 2 -transformed SIs are shown. Colors indicate the CV within each set of three replicates at each site, with overall CV between sites shown at the top for each donor. (D) Percent CV in CD4 + and CD8 + T cell AIM SIs calculated between technical replicate AIM assays within each site for unstimulated, pp65-stimulated, and spike-stimulated conditions. Each point represents the CV of three technical replicates within one site; bars represent individual donors. CV means with SD are shown. (E and F) ICCs comparing technical variability among CD4 + and CD8 + AIM responses to (E) CMV pp65 and (F) SARS-CoV-2 spike, using data from replicate AIM assays from different sites and donors. Bars represent the mean ICC for each AIM across all sites. (G and H) Percent CV in CD4 + and CD8 + T cell AIM responses to (G) CMV pp65 and (H) SARS-CoV-2 spike between the sites, calculated after averaging three technical replicate AIM assays per site. Each point represents one donor. Error bars represent 95% confidence interval of the mean. (I) ICCs comparing calculated technical variability for replicate AIM assays between sites to biological variability between donors for CD4 + and CD8 + T cells. Dotted lines represent CV = 30% (in D, G and H) and indicate ICC = 0.5 (equal biological and technical variability) (E, F, and I).

Journal: Cell Reports Methods

Article Title: Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows

doi: 10.1016/j.crmeth.2026.101458

Figure Lengend Snippet: CMV- and SARS-CoV-2-specific AIM assays are reproducible within and between research centers (A) Experimental design for AIM assay inter-site testing. Replicate aliquots of PBMCs from n = 6 healthy donors assayed in three independent experiments (individual points) by four research groups (coded A–D). Replicate AIM assay experiments ( n = 3 per donor, per site) were performed by stimulating PBMCs for 20 h with CMV pp65 or SARS-CoV-2 spike peptides. (B and C) Box-Cox-corrected SIs of CD134 + CD25 + frequencies among CD4 + T cells and CD137 + CD69 + among CD8 + T cells. Means and SD of log 2 -transformed SIs are shown. Colors indicate the CV within each set of three replicates at each site, with overall CV between sites shown at the top for each donor. (D) Percent CV in CD4 + and CD8 + T cell AIM SIs calculated between technical replicate AIM assays within each site for unstimulated, pp65-stimulated, and spike-stimulated conditions. Each point represents the CV of three technical replicates within one site; bars represent individual donors. CV means with SD are shown. (E and F) ICCs comparing technical variability among CD4 + and CD8 + AIM responses to (E) CMV pp65 and (F) SARS-CoV-2 spike, using data from replicate AIM assays from different sites and donors. Bars represent the mean ICC for each AIM across all sites. (G and H) Percent CV in CD4 + and CD8 + T cell AIM responses to (G) CMV pp65 and (H) SARS-CoV-2 spike between the sites, calculated after averaging three technical replicate AIM assays per site. Each point represents one donor. Error bars represent 95% confidence interval of the mean. (I) ICCs comparing calculated technical variability for replicate AIM assays between sites to biological variability between donors for CD4 + and CD8 + T cells. Dotted lines represent CV = 30% (in D, G and H) and indicate ICC = 0.5 (equal biological and technical variability) (E, F, and I).

Techniques: Transformation Assay

An automated gating pipeline performs comparably to manual analysis for AIM assays (A) Individuals were trained on identical gating protocols and analyzed the same data files from three technical replicates of 20-h AIM assays with CMV pp65 or SARS-CoV-2 spike peptides on healthy donor PBMCs ( n = 6) collected at four sites designated A–D. Raw flow cytometric data from each replicate at each site were analyzed independently by 3 individuals. Data represent CVs between analysts as the mean CV (with error bars showing 95% CIs) for the three technical replicates of each donor-site combination. (B and C) An automated AIM gating pipeline was created; flow cytometric gating approaches comparing manual and automated analyses are shown for (B) CD4 + CD134 + /CD25 + T cells and (C) CD8 + CD137 + /CD69 + T cells. The CytoStim condition was used by the automated software to set donor-specific AIM gates, which were then applied to other stimulations. (D–F) Automated and manual analyses of multi-center CMV and SARS-CoV-2 AIM assay data. A central analyst (C1) defined the gating strategy, provided instructions to the manual analysts (C2 and O1–O4), and was the reference for comparisons. C1, C2, and the automated software each analyzed all data from all sites, while O1–O4 each analyzed data from a single site (O1: A; O2: B; O3: C; O4: D). Box-Cox-corrected AIM SI values are shown for (D) CMV and (E) SARS-CoV-2 AIM assays. p values represent paired comparisons between each analyst and C1 from post-hoc Dunnett’s multiple comparisons test following mixed-effects analysis and were used to compute (F) total numbers of comparisons for C2 and automated analyses that significantly differed from C1 for CD4 + AIMs, with each of the 32 combinations of CD4 + AIM, site, and antigen (CMV or SARS-CoV-2) considered one comparison. Pooled comparisons were analyzed using Fisher’s exact test. (G–I) Spearman’s correlations of AIM SI values for C1, C2, O1–O4 (pooled), and automated analyses for CMV and SARS-CoV-2. Comparisons are shown against (G and H) the reference C1 and (I) for each analyst against all others in a correlation matrix. (J) F1 scores calculated for C2 manual vs. C1 reference (gray) or automated vs. C1 reference (green) analysis. Each point represents the F1 score from a unique donor-site combination, with p values from paired Wilcoxon signed-rank test after averaging F1 scores from technical replicates.

Journal: Cell Reports Methods

Article Title: Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows

doi: 10.1016/j.crmeth.2026.101458

Figure Lengend Snippet: An automated gating pipeline performs comparably to manual analysis for AIM assays (A) Individuals were trained on identical gating protocols and analyzed the same data files from three technical replicates of 20-h AIM assays with CMV pp65 or SARS-CoV-2 spike peptides on healthy donor PBMCs ( n = 6) collected at four sites designated A–D. Raw flow cytometric data from each replicate at each site were analyzed independently by 3 individuals. Data represent CVs between analysts as the mean CV (with error bars showing 95% CIs) for the three technical replicates of each donor-site combination. (B and C) An automated AIM gating pipeline was created; flow cytometric gating approaches comparing manual and automated analyses are shown for (B) CD4 + CD134 + /CD25 + T cells and (C) CD8 + CD137 + /CD69 + T cells. The CytoStim condition was used by the automated software to set donor-specific AIM gates, which were then applied to other stimulations. (D–F) Automated and manual analyses of multi-center CMV and SARS-CoV-2 AIM assay data. A central analyst (C1) defined the gating strategy, provided instructions to the manual analysts (C2 and O1–O4), and was the reference for comparisons. C1, C2, and the automated software each analyzed all data from all sites, while O1–O4 each analyzed data from a single site (O1: A; O2: B; O3: C; O4: D). Box-Cox-corrected AIM SI values are shown for (D) CMV and (E) SARS-CoV-2 AIM assays. p values represent paired comparisons between each analyst and C1 from post-hoc Dunnett’s multiple comparisons test following mixed-effects analysis and were used to compute (F) total numbers of comparisons for C2 and automated analyses that significantly differed from C1 for CD4 + AIMs, with each of the 32 combinations of CD4 + AIM, site, and antigen (CMV or SARS-CoV-2) considered one comparison. Pooled comparisons were analyzed using Fisher’s exact test. (G–I) Spearman’s correlations of AIM SI values for C1, C2, O1–O4 (pooled), and automated analyses for CMV and SARS-CoV-2. Comparisons are shown against (G and H) the reference C1 and (I) for each analyst against all others in a correlation matrix. (J) F1 scores calculated for C2 manual vs. C1 reference (gray) or automated vs. C1 reference (green) analysis. Each point represents the F1 score from a unique donor-site combination, with p values from paired Wilcoxon signed-rank test after averaging F1 scores from technical replicates.

Techniques: Software, Comparison

Induction of LFs and anti-RABV-G IgG production by SAM-LNP1 in human LF chips (A) Schematic of the LF Chip created with monocytes and conditioned medium from the intramuscular vaccination-mimicking module created with BioRender.com . (B) Representative 3D confocal microscopic stacks showing pseudo-colored follicles (blue) and cell nuclei (green) present within extracellular matrix (ECM) gels cultured for 4 days within a perfused LF Chip when vaccinated with SAM-LNP1 in the absence or presence of IL-2 and IL-4 (SAM-LNP1 + IL-2&IL-4); scale bars, 100 μm. (C) Quantification of the number (left) and size (right) of LFs in LF chips of one donor based on immunostaining followed by confocal imaging. Each data point represents one field of view (left) or an individual follicle (right); 2 independent chips were analyzed per condition. (D) Anti-RABV-G IgG levels in effluents of no treatment LF chips or chips vaccinated with or without IL-2 and IL-4 and cultured for 14 days were detected using a cell-based assay; 3–4 independent chips were analyzed per condition. (E) Quantification of the number (left) and size (right) of LFs in LF chips from four different donors, with each color representing a different donor. Each data point corresponds to one field of view (left) or an individual follicle (right). (F) Anti-RABV-G IgG levels in effluents of LF chips. Each data point represents one chip, with different symbols indicating chips from three independent donors. (G) Anti-RABV-G IgG levels in effluents of LF chips seeded with naive B + bulk T + monocyte mixture. Each data point represents one chip, with different symbols indicating chips from three independent donors. (H) Heatmap showing average log2 fold changes in cytokine levels in the effluents of three LF chips created using bulk lymphocytes from donors whose prior exposure to rabies was unknown, measured using a Luminex Multiplex Assay at various time points (4, 7, 15, 22, and 28 days post-vaccination) compared to the average levels of each cytokine found at day 1. Representative results from one donor are shown in (B)–(D) and (H), with similar outcomes observed in two donors. Data shown are mean ± SD; (C, left; D; and E) one way ANOVA test followed by Tukey’s multiple comparisons test, (C, right; and E) Mann-Whitney U test, (F and G) Welch’s t test.

Journal: iScience

Article Title: In vitro recapitulation of intramuscular mRNA vaccination with naive and recall antigens using a human lymphoid follicle chip platform

doi: 10.1016/j.isci.2026.116416

Figure Lengend Snippet: Induction of LFs and anti-RABV-G IgG production by SAM-LNP1 in human LF chips (A) Schematic of the LF Chip created with monocytes and conditioned medium from the intramuscular vaccination-mimicking module created with BioRender.com . (B) Representative 3D confocal microscopic stacks showing pseudo-colored follicles (blue) and cell nuclei (green) present within extracellular matrix (ECM) gels cultured for 4 days within a perfused LF Chip when vaccinated with SAM-LNP1 in the absence or presence of IL-2 and IL-4 (SAM-LNP1 + IL-2&IL-4); scale bars, 100 μm. (C) Quantification of the number (left) and size (right) of LFs in LF chips of one donor based on immunostaining followed by confocal imaging. Each data point represents one field of view (left) or an individual follicle (right); 2 independent chips were analyzed per condition. (D) Anti-RABV-G IgG levels in effluents of no treatment LF chips or chips vaccinated with or without IL-2 and IL-4 and cultured for 14 days were detected using a cell-based assay; 3–4 independent chips were analyzed per condition. (E) Quantification of the number (left) and size (right) of LFs in LF chips from four different donors, with each color representing a different donor. Each data point corresponds to one field of view (left) or an individual follicle (right). (F) Anti-RABV-G IgG levels in effluents of LF chips. Each data point represents one chip, with different symbols indicating chips from three independent donors. (G) Anti-RABV-G IgG levels in effluents of LF chips seeded with naive B + bulk T + monocyte mixture. Each data point represents one chip, with different symbols indicating chips from three independent donors. (H) Heatmap showing average log2 fold changes in cytokine levels in the effluents of three LF chips created using bulk lymphocytes from donors whose prior exposure to rabies was unknown, measured using a Luminex Multiplex Assay at various time points (4, 7, 15, 22, and 28 days post-vaccination) compared to the average levels of each cytokine found at day 1. Representative results from one donor are shown in (B)–(D) and (H), with similar outcomes observed in two donors. Data shown are mean ± SD; (C, left; D; and E) one way ANOVA test followed by Tukey’s multiple comparisons test, (C, right; and E) Mann-Whitney U test, (F and G) Welch’s t test.

Article Snippet: Human Interleukin-4 (IL-4) , Miltenyi Biotec , 130-093-922.

Techniques: Cell Culture, Immunostaining, Imaging, Cell Based Assay, Luminex, Multiplex Assay, MANN-WHITNEY

Review

vegf a (Miltenyi Biotec)

Structured Review

Images

Related Articles

Recombinant:

Isolation:

Control:

Cell Culture:

Sequencing:

other:

Similar Products

Image Search Results